See all articles by Alexis J. CombesUniversity of California, San Francisco (UCSF) - UCSF CoLabs
University of California, San Francisco (UCSF) - Department of Pathology
University of California, San Francisco (UCSF) - Department of Pathology
University of California, San Francisco (UCSF) - Department of Pathology
University of California, San Francisco (UCSF) - Department of Pathology
University of California, San Francisco (UCSF) - Department of Pathology
University of California, San Francisco (UCSF) - Department of Pathology
University of California, San Francisco (UCSF) - Department of Pathology
University of California, San Francisco (UCSF) - ImmunoX Initiative
University of California, San Francisco (UCSF) - UCSF CoLabs
University of California, San Francisco (UCSF) - UCSF CoLabs
University of California, San Francisco (UCSF) - Department of Pathology
University of California, San Francisco (UCSF) - Department of Pathology
Fred Hutchinson Cancer Research Center - Translational Research Program
University of California, San Francisco (UCSF) - Department of Pathology
University of California, San Francisco (UCSF) - Department of Pathology
Aix-Marseille University - Centre d'Immunologie de Marseille-Luminy
University of California, San Francisco (UCSF) - UCSF CoLabs
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center
Independent
University of California, San Francisco (UCSF) - Department of Pathology
University of California, San Francisco (UCSF) - Department of Pathology
University of California, San Francisco (UCSF) - Department of Pathology
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco (UCSF) - Department of Obstetrics, Gynecology and Reproductive Sciences
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco (UCSF) - Division of Hematology and Oncology
University of California, San Francisco (UCSF) - Department of Medicine; University of California, San Francisco (UCSF) - Department of Dermatology
University of California, San Francisco (UCSF) - Department of Otolaryngology
University of California, San Francisco (UCSF) - Department of Neurological Surgery
University of California, San Francisco (UCSF) - ImmunoX Initiative
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco (UCSF) - UCSF CoLabs
University of California, San Francisco (UCSF) - UCSF CoLabs
Sorbonne University - Centre d'Immunologie et des Maladies Infectieuses
University of California, San Francisco (UCSF) - Department of Epidemiology and Biostatistics
University of California, San Francisco (UCSF) - Department of Microbiology and Immunology
University of California, San Francisco (UCSF) - Department of Pathology; University of California, San Francisco (UCSF) - Department of Anatomy
Abstract
Cancers display significant heterogeneity with respect to tissue of origin, driver mutations and other features of the surrounding tissue. It is likely that persistent tumors differentially engage inherent patterns–here ‘Archetypes’–of the immune system, to both benefit from a tumor immune microenvironment (TIME) and to disengage tumor-targeting. To discover dominant immune system archetypes, the Immunoprofiler Initiative (IPI) processed 364 individual tumors across 12 cancer types using standardized protocols. Computational clustering of flow cytometry and transcriptomic data obtained from cell sub compartments uncovered archetypes that exist across indications. These Immune composition-based archetypes differentiate tumors based upon unique immune and tumor gene-expression patterns. Archetypes discovered this way also tie closely to well-established classifications of tumor biology. The IPI resource provides a template for understanding cancer immunity as a collection of dominant patterns of immune infiltration and provides a rational path forward to learn how to modulate these patterns to improve therapy.
Combes, Alexis J. and Samad, Bushra and Tsui, Jessica and Chew, Nayvin W. and Yan, Peter and Reeder, Gabriella C. and Kushnoor, Divyashree and Shen, Alan and Davidson, Brittany and Barczak, Andrea J. and Adkisson, Michael and Edwards, Austin and Naser, Mohammad and Barry, Kevin C. and Courau, Tristan and Hammoudi, Taymour and Arguello, Rafael and Rao, Arjun Arkal and Olshen, Adam B. and Consortium, The Immunoprofiler and Cai, Cathy and Zhan, Jenny and Davis, Katelyn C. and Kelley, Robin K. and Chapman, Jocelyn S. and Attreya, Chloe E. and Patel, Amar and Daud, Adil and Ha, Patrick and Diaz, Aaron A. and Kratz, Johannes R. and Collisson, Eric A. and Fragiadakis, Gabriela K. and Erle, David J. and Boissonnas, Alexandre and Asthana, Saurabh and Chan, Vincent and Krummel, Matthew F., A Pan-Cancer Census of Dominant Tumor Immune Archetypes. Available at SSRN:
https://ssrn.com/abstract=3833003 or
http://dx.doi.org/10.2139/ssrn.3833003
Download This Paper